Free Trial

Schonfeld Strategic Advisors LLC Buys New Stake in Inhibrx, Inc. (NASDAQ:INBX)

Inhibrx logo with Medical background

Schonfeld Strategic Advisors LLC bought a new stake in Inhibrx, Inc. (NASDAQ:INBX - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 144,178 shares of the company's stock, valued at approximately $2,220,000. Schonfeld Strategic Advisors LLC owned about 1.00% of Inhibrx as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in the stock. PNC Financial Services Group Inc. acquired a new position in shares of Inhibrx in the fourth quarter worth $28,000. Natixis purchased a new stake in Inhibrx during the 4th quarter worth about $31,000. China Universal Asset Management Co. Ltd. purchased a new stake in Inhibrx during the 4th quarter worth about $47,000. New York State Common Retirement Fund purchased a new stake in Inhibrx during the 4th quarter worth about $53,000. Finally, Corebridge Financial Inc. purchased a new stake in Inhibrx during the 4th quarter worth about $89,000. Institutional investors and hedge funds own 82.46% of the company's stock.

Wall Street Analysts Forecast Growth

Separately, JMP Securities restated a "market perform" rating on shares of Inhibrx in a report on Wednesday, January 22nd.

View Our Latest Analysis on Inhibrx

Inhibrx Price Performance

NASDAQ INBX traded down $0.08 during trading hours on Friday, hitting $11.18. 77,931 shares of the company were exchanged, compared to its average volume of 186,181. The company has a 50 day moving average of $12.82 and a two-hundred day moving average of $13.78. Inhibrx, Inc. has a 52-week low of $10.80 and a 52-week high of $34.73.

Inhibrx (NASDAQ:INBX - Get Free Report) last posted its earnings results on Monday, March 17th. The company reported ($3.09) EPS for the quarter, missing the consensus estimate of ($2.88) by ($0.21). The company had revenue of $0.10 million during the quarter. Analysts forecast that Inhibrx, Inc. will post 104.88 EPS for the current fiscal year.

Inhibrx Company Profile

(Free Report)

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.

Featured Articles

Institutional Ownership by Quarter for Inhibrx (NASDAQ:INBX)

Should You Invest $1,000 in Inhibrx Right Now?

Before you consider Inhibrx, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inhibrx wasn't on the list.

While Inhibrx currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

NVIDIA Earnings Preview: HUGE Stock Move Ahead
These 5 Small Stocks Could Deliver Huge Returns
ACT FAST! Congress Is POURING Into This Stock

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines